Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α

Autor: Morrow, Christopher, Carnevalli, Larissa, Baird, Richard D, Brier, Tim, Ciardullo, Carmela, Cureton, Natalie, Lawson, Mandy, McEwen, Robert, Nikolaou, Myria, Armstrong, Anne, Bermejo, Begoña, Calvo, Emiliano, Ciruelos, Eva, Garcia-Corbacho, Javier, Hamilton, Erika, Incorvati, Jason, Kabos, Peter, Oliveira, Mafalda, Patel, Manish R, Ruiz-Borregó, Manuel, Turner, Nicholas, Twelves, Chris, Vaklavas, Christos, Carroll, Danielle, Ching, Steven, Cvetesic, Nevena, DuPont, Michelle, Gibbons, Lisa, Mathewson, Alastair, Maudsley, Rhiannon, Gutierrez, Pablo Morentin, Reddy, Avinash, Rodriguez-Canales, Jaime, Ros, Susana, Sudhan, Dhivya, Sykes, Andy, Whitson, David, Klinowska, Teresa, Lindemann, Justin

Publikováno v: Cancer Research. 83:P3-07

Endocrine therapy forms the backbone treatment for patients with estrogen receptor (ER) positive tumors in both the adjuvant and metastatic setting. Aromatase inhibitors (AI) are the most common endocrine treatment option. Mutation of ESR1, the gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::261dc692da1168067bd2ea61374bbb0c
https://doi.org/10.1158/1538-7445.sabcs22-p3-07-13

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase i open-label study to identify a dosing regimen of the pan-akt inhibitor azd5363 for evaluation in solid tumors and in pik3ca-mutated breast and gynecologic cancers

Autor: Banerji, Udai, Dean, Emma J, Pérez-Fidalgo, J Alejandro, Batist, Gerald, Bedard, Philippe L, You, Benoit, Westin, Shannon N, Kabos, Peter, Garrett, Michelle D, Tall, Mathew, Ambrose, Helen, Barrett, J Carl, Carr, T Hedley, Cheung, S Y Amy, Corcoran, Claire, Cullberg, Marie, Davies, Barry R, de Bruin, Elza C, Elvin, Paul, Foxley, Andrew, Lawrence, Peter, Lindemann, Justin P O, Maudsley, Rhiannon, Pass, Martin, Rowlands, Vicky, Rugman, Paul, Schiavon, Gaia, Yates, James, Schellens, Jan H M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Banerji, U, Dean, E J, Alejandro Perez-Fidalgo, J, Batist, G, Bedard, P L, You, B, Westin, S N, Kabos, P, Garrett, M D, Tall, M, Ambrose, H, Carl Barrett, J, Hedley Carr, T, Amy Cheung, S Y, Corcoran, C, Cullberg, M, Davies, B R, de Bruin, E C, Elvin, P, Foxley, A, Lawrence, P, Lindemann, J P O, Maudsley, R, Pass, M, Rowlands, V, Rugman, P, Schiavon, G, Yates, J & Schellens, J H M 2018, ' A phase i open-label study to identify a dosing regimen of the pan-akt inhibitor azd5363 for evaluation in solid tumors and in pik3ca-mutated breast and gynecologic cancers ', Clinical Cancer Research, vol. 24, no. 9, pp. 2050-2059 . https://doi.org/10.1158/1078-0432.CCR-17-2260
Clinical Cancer Research, 24(9), 2050. American Association for Cancer Research Inc.

Purpose: This phase I, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in patients with advanced solid malignancies. The objectives were to investigate the safety,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9c020a5c61eecaf0eff435c10ecd12
https://doi.org/10.1158/1078-0432.CCR-17-2260

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.